MarketPulse

NCCN guidelines

3 articles
BenzingaBenzinga··Vandana Singh

FDA Warns ImmunityBio Over Anktiva Cancer Claims Despite Strong 750% Sales Surge

FDA flagged ImmunityBio for unsupported Anktiva cancer cure claims. Company implemented corrective measures while reporting 750% unit volume growth and $38.29M quarterly revenue.
IBRXsales growthregulatory compliance
BenzingaBenzinga··Vandana Singh

ImmunityBio Surges on NCCN Bladder Cancer Guideline Inclusion for Anktiva

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.
IBRXbladder cancerAnktiva
GlobeNewswire Inc.GlobeNewswire Inc.··Castle Biosciences, Inc.

Castle Biosciences' Melanoma Test Validates Risk Stratification in Landmark 912-Patient Study

Castle Biosciences' DecisionDx-Melanoma test confirmed 2.6% nodal positivity in 912 patients predicted low-risk, supporting safe SLNB avoidance and validating the diagnostic platform.
CSTLgene expression profileprecision oncology